For B2B peptide buyers, supply reliability matters as much as product price. A single production site creates a single point of failure: equipment downtime, regulatory inspection, logistics disruption or a capacity spike can all delay orders. A dual-base production model spreads production across two coordinated facilities, which is why supply-chain resilience has become a key consideration in peptide sourcing.

The Dual-Base Layout

Vitalis operates coordinated production bases covering peptide synthesis, purification, lyophilization and packaging, with quality control records and COA documentation maintained across both sites. The two bases share standardized operating procedures, purity targets and documentation requirements, while allowing different technical routes and product lines to be allocated according to capacity and specialization.

Advantages of the Dual-Base Model

How the Production Flow Works

A typical order moves through research and custom synthesis, pilot-scale confirmation, scale-up production, QC testing and final packaging. The dual-base structure lets R&D and small-batch work stay flexible while larger volume production is allocated to the site best suited to that product line. Batch numbers, test results and COA records travel with each shipment so the buyer can trace material back to its production source.

Typical Application Scenarios

Quality and Traceability

Resilience does not replace quality control. Every batch should still carry a COA with purity, identity, moisture and other test results, along with a traceable batch number. Buyers can request documentation before placing volume orders to confirm that both production sites follow the same testing and record-keeping standards.

Questions Buyers Commonly Ask

The dual-base model is presented here for B2B supply planning context. Products are research-use materials, not for human, veterinary, food or cosmetic application.